Chinook Therapeutics to Host Conference Call and Webcast Featuring BION-1301 Data Presented at the 58th ERA-EDTA Congress
May 25 2021 - 4:05PM
Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical
company focused on the discovery, development and commercialization
of precision medicines for kidney diseases, today announced that
the company will host a live conference call and webcast on
Tuesday, June 8, 2021 at 1:00 pm PDT to discuss the interim data
from Part 3 of Chinook’s ongoing phase 1b study of BION-1301 in
patients with IgA nephropathy that will be presented at the 58th
ERA-EDTA Congress. Members of the Chinook executive team will be
joined by Dr. Jonathan Barratt, the Mayer Professor of Renal
Medicine at University of Leicester.
Details of the BION-1301 abstract accepted as an oral
presentation at the 58th ERA-EDTA Congress is as follows:
Presentation ID
FC040: |
Interim Results of Phase 1 and 2
Trials to Investigate the Safety, Tolerability, Pharmacokinetics,
Pharmacodynamics, and Clinical Activity of BION-1301 in Patients
with IgA Nephropathy |
|
|
Author: |
Jonathan Barratt, Ph.D., F.R.C.P,
University of Leicester & Leicester General Hospital,
Leicester, United Kingdom |
|
|
Session: |
Treatment & outcome of
glomerulonephritis, Tuesday, June 8, 2021 at 8:30 – 10:00 am
CEST |
|
|
For more information, please visit the ERA-EDTA website located
at https://www.era-edta.org/en/virtualcongress2021/.
Conference Call and DetailsTo access the call,
please dial (844) 309-0604 (domestic) or (574) 990-9932
(international) and provide the Conference ID 2591818 to the
operator.
To access the live webcast and subsequent archived recording of
this and other company presentations, please visit the Investors
section of Chinook’s website. The archived webcast will remain
available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.Chinook
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
developing precision medicines for kidney diseases. Chinook’s
product candidates are being investigated in rare, severe chronic
kidney disorders with opportunities for well-defined clinical
pathways. Chinook’s lead program is atrasentan, a phase 3
endothelin receptor antagonist for the treatment of IgA nephropathy
and other proteinuric glomerular diseases. BION-1301, an anti-APRIL
monoclonal antibody is being evaluated in a phase 1b trial for IgA
nephropathy. In addition, Chinook is advancing CHK-336, an oral
small molecule LDHA inhibitor for the treatment of primary
hyperoxaluria, as well as research programs for other rare, severe
chronic kidney diseases. Chinook is building its pipeline by
leveraging insights in kidney single cell RNA sequencing,
human-derived organoids and new translational models, to discover
and develop therapeutics with differentiating mechanisms of action
against key kidney disease pathways. To learn more, visit
www.chinooktx.com.
Contact:Noopur LiffickVice President, Investor
Relations & Corporate Communicationsinvestors@chinooktx.com
media@chinooktx.com
Chinook Therapeutics (NASDAQ:KDNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chinook Therapeutics (NASDAQ:KDNY)
Historical Stock Chart
From Sep 2023 to Sep 2024